Clinical trials: Mucormycosis
Mucormycosis
Mucorales PCR Screening in At-risk Hematology Patients
Patients with leukemia are treated with intensive chemotherapy and often have to undergo a stem cell transplantation which makes their immune system extremely vulnerable.
- Trial name
- MUCOPS (NCT05925660)
- Testing
- Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Aspergillos, Mucormye
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Background: Fungal infections can cause serious disease in the lungs and other parts of the body. About 3.8 million people die with fungal infections each year.
- Conditions
- Aspergillos, Mucormye, Dimorphic, Other Molds
- Trial name
- NCT07704333
- Testing
- [18F]-Fluorocellobiose ([18F]FCB)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Mucormycosis
Rehabilitation With an Obturator in Maxillary Defects
During the COVID-19 pandemic, there was a lot of reporting of COVID-19-associated mucormycosis cases. Managing this condition posed a new challenge to clinicians.
- Trial name
- NCT06515743
- Testing
- Obturator Prosthetic Rehabilitation
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Menoufia University
Mucormycosis
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.
- Trial name
- NCT06878144
- Testing
- Mucormycosis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Hemifacial Microsomia, Mucormycosis
Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.
This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects.
- Conditions
- Hemifacial Microsomia, Mucormycosis, Oral Squamous Cell Carcinoma, Microgenia
- Trial name
- 3DFACE (NCT07654647)
- Testing
- Patient-specific titanium implants for facial reconstruction
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Latakia University
Mucorales Infection, Mucormycosis
Biomarkers for Invasive Mucormycosis
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization.
- Trial name
- BIM (NCT05406037)
- Testing
- Venous sample
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Mucormycosis; Pulmonary (Etiology)
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis.
- Trial name
- NCT05468372
- Testing
- Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Aspergillosis, Mucormycosis
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food…
- Trial name
- NCT04744454
- Testing
- Isauvuconazole group
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Pfizer
Mucormycosis, Hematologic Malignancies
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
The project intends to carry out a retrospective study on the epidemiology, predisposing factors, clinical manifestations, diagnosis, treatment, prognosis and economic burden of mucormycosis in a Chinese single-center allogeneic…
- Conditions
- Mucormycosis, Hematologic Malignancies, COVID-19
- Trial name
- NCT06900114
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pulmonary Mucormycosis
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients.
- Trial name
- RadioMucor (NCT07339800)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Invasive Aspergillosis, Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom).
- Trial name
- PRISMA (NCT04550936)
- Testing
- Isavuconazole
- Where
- 15 sites in France, Germany and 3 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Mucormycosis
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Background: Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole.
- Trial name
- AIM (NCT07191756)
- Testing
- Amphotericin B, Isavuconazole
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qiu Ye
Mucormycosis in Hematologic Malignancies
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
This clinical trial, a single-arm prospective study, aims to evaluate the efficacy and safety of liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole in treating adult patients with malignant…
- Trial name
- NCT07185503
- Testing
- liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Fungal Infection, Aspergillosis
Isavuconazole in Critically Ill Patients: Efficacy and Safety
Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in…
- Conditions
- Fungal Infection, Aspergillosis, Mucormycosis
- Trial name
- NCT07080359
- Testing
- Isavuconazole treatment
- Volunteers
- 75 people
- Sponsor
- Shanghai 10th People's Hospital
Pulmonary Mucormycosis
Antifungal Drugs in Pulmonary Mucormycosis
Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of…
- Trial name
- NCT06756191
- Testing
- Combination therapy group, Liposomal Amphotericin B
- Volunteers
- 312 people
- Sponsor
- Bin Cao
Aspergillosis Invasive, Mucormycosis
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric…
- Trial name
- NCT06440915
- Testing
- Theraputic drug monitoring, Isavuconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Invasive Mucormycosis, Invasive Aspergillosis
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
- Trial name
- NCT03816176
- Testing
- Isavuconazonium sulfate
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pulmonary Mucormycosis
Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis
Evaluation of the effectiveness and safety of transbronchoscopic local precision infusion of amphotericin B + transoral nebulized inhalation of amphotericin B + transbronchoscopic interventional debridement + liposomal…
- Trial name
- NCT06495905
- Testing
- transbronchoscopic interventional debridement
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Mucormycosis; Rhinocerebral (Etiology), COVID-19
World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt
Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection
- Trial name
- NCT06267326
- Testing
- debridment
- Where
- Egypt
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nasser Institute For Research and Treatment
Pulmonary Mucormycosis
Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis
To assess the safety and feasibility of combined inhalational and intravenous amphotericin B therapy for the treatment of pulmonary mucormycosis.
- Trial name
- NCT04502381
- Testing
- Inhaled amp B deoxycholate+intravenous liposomal amp B, Intravenous liposomal amphotericin B alone
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh